Stock Alert: Immunovant Spikes On Results Of Its IMVT-1401

Shares of clinical-stage biopharmaceutical company Immunovant, Inc. (IMVT) are climbing more than 11% Monday morning after the company announced positive results from its ongoing phase II Proof-of-Concept Study of its lead drug candidate, IMVT-1401, proposed for the treatment of Thyroid Eye disease.

IMVT is currently trading at $15.04. It has traded in the range of $8.34- $18.69 in the past one week.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT